Why Vascular Aging May Drive Multimorbidity and What Stands in the Way of Treating It

Blood vessels age along with the rest of the body, and that aging is a leading determinant of cardiovascular risk. It also contributes to wider organismal decline, which is why the authors frame vascular aging as a central driver of multimorbidity. If vessel aging could be slowed or reversed, the benefits might extend well beyond the heart.

This is a narrative review, not a new experiment. The authors first describe the core mechanisms of vascular aging: epigenetic drift, chronic low-grade inflammation, and cellular senescence. They point to clinically relevant targets, including the IL-1β inflammatory pathway and populations of senescent cells. They then appraise current and emerging therapies, including repurposed metabolic drugs such as SGLT2 inhibitors, mitochondrial antioxidants such as MitoQ, and newer senolytic and gene therapy approaches.

The central conclusion concerns translation rather than new data. Three bottlenecks are emphasized: animal models do not map cleanly onto human biology, drugs are difficult to target to the vascular wall, and there are no validated surrogate endpoints that would let trials read out vascular aging quickly.

The authors outline a roadmap to address these gaps. It includes precision medicine approaches that match interventions to biological profiles, innovative clinical trial designs, and liquid biopsy biomarkers to track vascular aging and speed therapy development.

Caveats are important. Only the abstract was available, so details on the evidence behind each therapy, including how strong or human-based it is, cannot be assessed here. A review of this kind reflects the authors' selection and interpretation of the literature. Therapies like senolytics and gene therapy remain largely investigational for vascular aging.